Case study
Communicating the brand and science of Immunocore
My role: Design Lead / contributor
Project type: Client project
Year: 2012
My contributions: Client leadership, Design direction, Brand design, Science communication
Outcome: Brand and science comms materials in use for over a decade (and counting)
The Challenge
Immunocore is a $1.73 bn Nasdaq-listed company that developed the world’s first approved T cell receptor therapy (based on the ImmTAX technology).
In 2012, I was asked to build a visual science communication pack to explain how ImmTAX kills cancer cells and to mature the brand.
My Approach
I facilitated co-creation workshops to generate concepts for explanatory graphics, diagrams, and logos. Iteratively, I turned these into final visual assets that Immunocore used on their website, conference posters, and publications.
Story concepts and early sketches of ImmTAX engineering co-designed with Immunocore’s science team.
The Solution
I designed Immunocore’s new logotype, brand manual, science communications graphics, videos, and business templates.
The Result
The logotype has been in use for over 13 years now, including appearing on the Nasdaq Tower in Times Square, NY for Immunocore’s stock exchange debut in 2021.
Science communications materials were in use for about 10 years until company's IPO.
ImmTAX engineering and antigen presentation on cell survace.
ImmTAX mediates in T cell killing of a cancer cell (with cytokine release).
